Risk of ptosis following eyelid speculum assisted intravitreal anti-VEGF injections.

IF 2.4 3区医学 Q2 OPHTHALMOLOGY

Graefe’s Archive for Clinical and Experimental Ophthalmology Pub Date : 2025-02-13 DOI:10.1007/s00417-025-06763-3

Efraim Berco, Michael Ostrovsky, Obinna Esomchukwu, Ortal Zaks, Mor Schlesinger, Elkin Jose Cervantes Molina, Shalhevet Goldfeather Ben-Zaken, Nir Shoham-Hazon

{"title":"Risk of ptosis following eyelid speculum assisted intravitreal anti-VEGF injections.","authors":"Efraim Berco, Michael Ostrovsky, Obinna Esomchukwu, Ortal Zaks, Mor Schlesinger, Elkin Jose Cervantes Molina, Shalhevet Goldfeather Ben-Zaken, Nir Shoham-Hazon","doi":"10.1007/s00417-025-06763-3","DOIUrl":null,"url":null,"abstract":"Purpose: Intravitreal injections are essential for treating retinal diseases. This study aims to assess the impact of repeated intravitreal anti-VEGF injections using an eyelid speculum on the risk of ptosis development.Methods: This single-center, retrospective chart review included 114 patients (228 eyes) who received at least three unilateral intravitreal anti-VEGF injections. Patient demographics, clinical characteristics, and MRD1 and MRD2 of the injected and the fellow eyes were analyzed. A multivariate linear regression model was constructed to identify predictors of MRD1 in the injected eye.Results: The study cohort had a mean age of 75.18 ± 0.98 years, with 57% female patients. On average, patients received 16.92 ± 1.18 injections. At the final follow-up, no significant difference was observed in mean MRD1 between injected and fellow eyes (2.85 ± 0.11 mm vs. 2.90 ± 0.11 mm, p = 0.445). Multivariate regression analysis identified MRD1 of the fellow eye as the only significant predictor of MRD1 in the injected eye (β = 0.769, p < 0.001).Conclusion: The repeated use of an eyelid speculum during intravitreal anti-VEGF injections does not significantly contribute to ptosis development. MRD1 tends to be similar between the injected and non-injected eye, suggesting that intrinsic factors may play a more crucial role in determining eyelid position than the mechanical effects of the procedure.","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Graefe’s Archive for Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00417-025-06763-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Intravitreal injections are essential for treating retinal diseases. This study aims to assess the impact of repeated intravitreal anti-VEGF injections using an eyelid speculum on the risk of ptosis development.

Methods: This single-center, retrospective chart review included 114 patients (228 eyes) who received at least three unilateral intravitreal anti-VEGF injections. Patient demographics, clinical characteristics, and MRD1 and MRD2 of the injected and the fellow eyes were analyzed. A multivariate linear regression model was constructed to identify predictors of MRD1 in the injected eye.

Results: The study cohort had a mean age of 75.18 ± 0.98 years, with 57% female patients. On average, patients received 16.92 ± 1.18 injections. At the final follow-up, no significant difference was observed in mean MRD1 between injected and fellow eyes (2.85 ± 0.11 mm vs. 2.90 ± 0.11 mm, p = 0.445). Multivariate regression analysis identified MRD1 of the fellow eye as the only significant predictor of MRD1 in the injected eye (β = 0.769, p < 0.001).

Conclusion: The repeated use of an eyelid speculum during intravitreal anti-VEGF injections does not significantly contribute to ptosis development. MRD1 tends to be similar between the injected and non-injected eye, suggesting that intrinsic factors may play a more crucial role in determining eyelid position than the mechanical effects of the procedure.

查看原文本刊更多论文

眼睑镜辅助玻璃体内抗vegf注射后上睑下垂的风险。

目的：玻璃体内注射是治疗视网膜疾病的必要手段。本研究旨在评估眼睑镜反复玻璃体内抗vegf注射对上睑下垂发展风险的影响。方法：这项单中心、回顾性图表回顾纳入了114例（228只眼）接受了至少三次单侧玻璃体内抗vegf注射的患者。分析患者的人口统计学特征、临床特征以及注射眼和同侧眼的MRD1和MRD2。建立多元线性回归模型以确定注射眼MRD1的预测因子。结果：研究队列的平均年龄为75.18±0.98岁，女性患者占57%。患者平均注射16.92±1.18次。在最后随访时，注射组和同组的平均MRD1无显著差异（2.85±0.11 mm比2.90±0.11 mm, p = 0.445）。多因素回归分析发现，同侧眼MRD1是注射眼MRD1的唯一显著预测因子（β = 0.769, p）。结论：玻璃体内注射抗vegf时反复使用眼睑窥镜对上睑下垂的发生无显著影响。MRD1在注射和未注射的眼睛之间趋于相似，这表明在决定眼睑位置方面，内在因素可能比手术的机械效应发挥更重要的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Graefe’s Archive for Clinical and Experimental Ophthalmology 医学-眼科学

CiteScore

5.40

自引率

7.40%

发文量

398

审稿时长

3 months

期刊介绍： Graefe''s Archive for Clinical and Experimental Ophthalmology is a distinguished international journal that presents original clinical reports and clini-cally relevant experimental studies. Founded in 1854 by Albrecht von Graefe to serve as a source of useful clinical information and a stimulus for discussion, the journal has published articles by leading ophthalmologists and vision research scientists for more than a century. With peer review by an international Editorial Board and prompt English-language publication, Graefe''s Archive provides rapid dissemination of clinical and clinically related experimental information.